“If you use it, you’re supposed to get permission to do it, even for research purposes, saidRobin Robinson, director of the Biomedical Advanced Research and Development Authority,part of the United States Department of Health and Human Services. He said the Chinesescientists might have infringed patents if they tried to sell MIL77 outside China without anagreement with Mapp Biopharmaceutical, the small American company with intellectualproperty rights to ZMapp.
“如果你使用它,你就应该获得许可,甚至是为了研究目的,美国卫生与公共服务部(Department of Healthand Human Services)属下的生物医学高级研究和发展管理局(Biomedical Advanced Research andDevelopment Authority)局长罗宾·罗宾逊(Robin Robinson)说道。他说,如果中国科学家试图在中国以外地区销售MIL77,却没有与拥有ZMapp知识产权的美国小型公司Mapp生物制药(Mapp Biopharmaceutical)达成协议的话,他们或许已经侵犯了专利。
Larry Zeitlin, president of Mapp, said the Chinese scientists had reached out to him aftercreating MIL77 and had been collaborative.
Mapp公司总裁拉里·泽特林(Larry Zeitlin)表示中国科学家已经在研制出MIL77之后与他接洽,并表现得愿意合作。
Dr. Robinson said his agency had worked with Mapp and larger companies — includingRegeneron in Tarrytown, N.Y., and Genentech in South San Francisco — to use methods similarto the Chinese researchers’ to increase production of ZMapp and other antibody-basedtreatments for Ebola.
【中国造埃博拉药物挽救生命 却卷入专利纠纷】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15